Risk factor
Very poor trading liquidity
Profitability factor
Strong growth
About
Shine-On BioMedical Co.,Ltd. is dedicated to the research, development, and manufacturing of pharmaceutical products aimed at combating cancer. The company's innovative pipeline features a range of antibody-based oncology therapies. These include exosome anti-cancer drugs like SOB101 and SOB102, as well as SOB201, an engineered multi-target exosome. Additionally, their portfolio encompasses specialized antibody treatments such as SOA101, a dual immune checkpoint T cell adapter, and SOA201, a trispecific adapter immune cell antibody. This Taiwanese firm, founded in 2021, is based in Taichung.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overvalued on P/FCF.